Key result
Tirapazamine derivatives diminished the cytotoxic effect of doxorubicin in rat H9C2 cardiomyocytes regardless of concentration and alkyl chain length, whereas tirapazamine itself showed no significant protective activity.
Why the study?
The study aimed to evaluate the interaction of newly synthesized tirapazamine derivatives with doxorubicin in rat cardiomyocytes using an in vitro model.
Do tirapazamine derivatives protect rat H9C2 cardiomyocytes from doxorubicin-induced cytotoxicity?
Do tirapazamine derivatives protect rat H9C2 cardiomyocytes from doxorubicin-induced cytotoxicity?
Newly synthesized tirapazamine derivatives with alkyl chain-connected triphenylphosphine cations protect H9C2 cardiomyocytes against doxorubicin-induced cytotoxicity in vitro.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for tirapazamine derivatives in doxorubicin cardiotoxicity; in vitro data leaves clinical translation open.
Doxorubicin cardiotoxicity is caused by various mechanisms, most importantly by oxidative stress originating in the mitochondria. Tirapazamine is a hypoxia-activated anticancer experimental drug. Both drugs in normoxia conditions undergo univalent reduction, thus tirapazamine may compete with doxorubicin in univalent reduction enzyme uptake. Herein, tirapazamine derivatives consisted of drug molecules and alkyl chain-connected triphenylphosphine cations that bring about an accumulation in mitochondria. The aim of this study was to evaluate the interaction of newly synthesized tirapazamine derivatives with doxorubicin in rat cardiomyocytes via an vitro model. In the work, H9C2 cells were incubated with combinations of doxorubicin, tirapazamine and seven variants of tirapazamine derivatives. After 24 hours, cell viability was assessed using MTT assay and the results were confirmed by microscopic observation. Tirapazamine in all tested concentrations did not revealed significant protective activity to cardiomyocytes treated with doxorubicine. However, tirapazamine derivatives diminished the cytotoxic effect of doxorubicin regardless of concentration and alkyl chain length. Tirapazamine derivatives have shown protective effects in relation to cardiomyocytes treated with doxorubicin and the mechanism of this phenomenon must be confirmed.
No takes yet. Share an insight, caveat, or question.
Korga-Plewko et al. (2020) studied Doxorubicin-induced cardiotoxicity. Tirapazamine derivatives vs. Doxorubicin alone (5 µM) was evaluated on Cell viability (MTT assay). Tirapazamine derivatives diminished the cytotoxic effect of doxorubicin in rat H9C2 cardiomyocytes regardless of concentration and alkyl chain length, whereas tirapazamine itself showed no significant protective activity.
Synapse has enriched 10 related papers. Consider them for comparative context: